General Bio Raises $7.4 Million Seed Round to Advance an Oral Peptide Delivery Platform for GLP-1 Weight-Loss Drugs and Other Peptide Therapeutics According to Monday July 20 Axios Pro Biotech Deals Exclusive Reporting; CEO David Kim Confirmed the Company Is Pursuing a Larger Follow-On Round to Scale Preclinical and Early Clinical Development Against Established Oral-Peptide Competitors Including Novo Nordisk's Wegovy Pill (Oral Semaglutide 25 mg), Merck's LIPFENDRA (Enlicitide) Oral PCSK9 Inhibitor, and MindRank AI's MDR-001 Phase 3 Chinese Oral GLP-1
General Bio, a developer of oral GLP-1s and other peptides, has raised $7.4 million and is pursuing a larger follow-on funding round, CEO David Kim told Axios Pro Biotech Deals in an exclusive report published Monday July 20, 2026. The company is one of several new-generation oral peptide startups seeking to compete against the established oral-peptide market, which now spans Novo Nordisk's Wegovy pill (oral semaglutide 25 mg, launched January 2026, over 3 million US prescriptions by June), Merck's LIPFENDRA (enlicitide, oral macrocyclic peptide PCSK9 inhibitor FDA-approved July 16, 2026), and MindRank AI's MDR-001 (AI-designed oral small-molecule GLP-1RA in Phase 3 MOBILE trial in China, $52M Series B closed July 9). The oral peptide category economics are shaped by macrocyclic peptide chemistry (Merck's LIPFENDRA approach) that allows survival through the gastrointestinal tract, permeation-enhancer formulations (Novo's SNAC technology for oral semaglutide), and next-generation delivery platforms including Rani Therapeutics' RaniPill capsule (July 9 collaboration announced with China's PegBio). Seed-stage entrants like General Bio typically position on proprietary chemistry or delivery mechanisms that could enable next-generation peptides beyond the current oral GLP-1 wave.